Countdown Widget

Join Us
9/17/2018

2018/9/17 07:30:00

Program Details

Location: St. Anthony Shrine,
100 Arch Street
Boston, MA
View Map
Date: September 17, 2018
Time: 7:30 AM - 3:50 PM

7:30—8:30 a.m. Registration and Breakfast

In-person registration available day of conference. Pre-register online now here. Continental Breakfast provided.

8:30—8:40 a.m. Welcome, Conference Overview, and Pre-activity Polling

8:45—9:15 a.m. The Challenge of HCV Elimination

9:15—9:45 a.m. Addressing Region-Specific Barriers and Challenges to HCV Elimination

Robert Greenwald, Harvard Law School

9:45—10:30 a.m. HCV Therapy: The State of the Union

Dr. Arthur Kim, Massachusetts General Hospital

10:30—10:45 a.m. Morning Break

10:45—11:30 a.m. Populations in Greatest Need—Men Who Have Sex With Men (MSM)

Dr. David Wyles, Denver Health

11:30 a.m.—12:15 p.m. Populations in Greatest Need—People Who Inject Drugs (PWID)

Dr. Camilla Graham, Beth Israel Deaconess Medical Center

12:15—1:00 p.m. Lunch

1:00—1:30 p.m. Other Real-World Circumstances: Corrections

Dr. Alysse Wurcel,  Tufts Medical Center

1:30—1:45 p.m. Success Stories

1:45—2 p.m. Introduction to Small-Group Breakouts: Bringing Together Stakeholders and Creating a Collaborative Plan

2:00—2:30 p.m. Multidisciplinary Small Groups: Putting a Plan into Action

2:30—3:30 p.m. Panel Discussion: The Call to Action & Beyond

3:30—3:50 p.m. Closing Statements & Post-activity Polling

David L. Wyles, MD (Course Chair)
Associate Professor of Medicine
University of Colorado School of Medicine
Chief, Division of Infectious Diseases
Denver Health
Denver, Colorado

Arthur Yu-Shin Kim, MD (Boston Co-Chair)
Associate Professor of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Department of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Camilla Graham, MD, MPH
Vice President, Medical and Government Affairs
TREK Therapeutics, PBC
Assistant Professor of Medicine
Harvard Medical School
Division of Infectious Disease
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Robert Greenwald
Faculty Director
Center for Health Law and Policy Innovation
Clinical Professor of Law
Harvard Law School
Cambridge, Massachusetts

Alysse Wurcel, MD, MS
Assistant Professor
Department of Medicine
Division of Geographic Medicine and Infectious Diseases
Tufts Medical Center
Department of Public Health and Community Medicine
Tufts University School of Medicine
Boston, Massachusetts

 

Target Audience

This activity is intended for a multidisciplinary audience including community-based infectious disease specialists and other human immunodeficiency virus (HIV) treaters, gastroenterology/hepatology clinicians, mental health specialists, substance abuse specialists, correctional health care professionals, public policy/public health officials, hepatitis C virus (HCV) and HIV advocacy groups, payers, and clinical office staff who are engaged in the care of patients with HIV and/or HCV.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe epidemiologic trends in HCV monoinfection and HIV/HCV coinfection within at-risk populations, including men who have sex with men (MSM), people who inject drugs (PWID), and incarcerated individuals
  • Screen MSM, PWID, and incarcerated individuals for HCV and HIV infection
  • Provide guideline-based treatment for HCV monoinfection and HIV/HCV coinfection
  • Identify patient, provider, and healthcare systembarriers to effective management of HCV monoinfection and HIV/HCV coinfection
  • Implement strategies to overcome risk-cohort–specific challenges to the treatment of HCV monoinfection and HIV/HCV coinfection

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 6.25 AMA PRA Category 1 CreditsTMPhysicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 6.25 contact hours (0.50 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA4008162-9999-18-003-L01-P)

Type of Activity

Application

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.  Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 6.3 contact hours.

Pharmacotherapy contact hours for Advanced Practice Registered Nurses to be determined.

Social Workers and Case Manager credit will be applied for, but is not guaranteed at this time.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are positioned to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com.

Fee Information

There is a $20.00 registration fee for attending this program.  Upon registration, you’ll be asked for payment information.

Website

For more information on the BLOCK HIV/HCV initiative, please visit: www.blockhivhcv.com

Resources

Considerations for Antiretroviral Use in Patients With Coinfections: Hepatitis C Virus/HIV Coinfection. US Department of Health and Human Services (DHHS), 2017 (last updated March 2018).

Patients With HIV/HCV Coinfection. American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA), 2017.

Getting Off Right: A Safety Manual for Injection Drug Users: Harm Reduction Coalition. The Harm Reduction Coalition has produced a compilation of unbiased medical facts, injection techniques, and common sense with the goal of reducing harm and promoting individual and community health.

Hep C 123: Diagnosis, Treatment & Support: American Liver Foundation, 2018. The American Liver Foundation’s Hep C 123 website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.

Project Inform: Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.

Hepatitis C and HIV Coinfection Booklets

Sex-C: Sex and Hepatitis C Prevention Tips for Gay Men

Sexual Transmission of Hepatitis C: A Guide for HIV-Positive Gay Men

Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men: a systematic review and meta-analysis. Hagan H, et al. AIDS. 2015;29(17):2335-2345.

Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Suryaprasad AG, et al. Clin Infect Dis. 2014;59(10):1411-1419.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. Virlogeux V, et al. BMC Med. 2017;15(1):217.

Mechanisms of accelerated liver fibrosis progression during HIV infection. Debes JD, et al. J Clin Transl Hepatol. 2016;4(4):328-335.

HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. Rallón N, et al. PLoS One. 2017;12(3):e0173943.

Emerging and underrecognized complications of illicit drug use.  Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.

Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Allyn PR, et al. Int J STD AIDS. 2018;29(4):334-340.

Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact.  MacGregor L, et al. Int J Epidemiol. 2017;46(5):1582-1592.

HIV/HCV co-infection: new guidelines, opportunities & challenges with the incarcerated population in the U.S. Fisher N. HIV Specialist. 2017;9(1):16-19.

Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.  Oramasionwu CU, et al. AIDS Patient Care STDS. 2014;28(5):228-239.

Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Bhattacharya D, et al. Clin Infect Dis. 2017;64(12):1711-1720.

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Bruno G, et al. Int J Infect Dis. 2017;62:64-71.

Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Collins LF, et al. Open Forum Infect Dis. 2017;5(1):ofx264.

High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center. Falade-Nwulia O, et al. Hepatology. 2017;66(5):1402-1412.

Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection. Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. Mínguez C, et al. AIDS. 2018;32(3):337-346.

Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. Rockstroh JK, et al. Clin Infect Dis. 2018. (Epub ahead of print).

Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Younossi ZM, et al. Liver Int. 2017;37(12):1796-1804.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Zeuzem S, et al. J Gastroenterol. 2018;53(5):679-688.

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Chhatwal J, et al. Aliment Pharmacol Ther. 2018;47(7):1023-1031.

The HCV care continuum does not end with cure: a call to arms for the prevention of reinfection. Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2):267-269.

Treatment of HCV in persons who inject drugs: treatment as prevention.  Grebely J, Dore GJ. Clin Liver Dis. 2017;9(4):77-80.

Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV. Young J, et al. Clin Infect Dis. 2017;64(9):1154-1162.


Comments are closed.